Results 131 to 140 of about 131,242 (269)

Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). [PDF]

Diabetes Care
Kahn SE, Tripputi M, Lachin JM, Balasubramanyam A, Banerji MA, Barzilay J, Cohen RM, Garvey WT, Gramzinski MR, Rasouli N, Rhee M, Seegmiller JC, Singh V, Sivitz WI, Steffes MW, Utzschneider K, DeFronzo RA, GRADE Research Group* .   +17 more
europepmc   +1 more source

Genetic variability in sodium-glucose cotransporter 2 and glucagon-like peptide 1 receptor effect on glycemic and pressure control in type 2 diabetes patients treated with SGLT2 inhibitors and GLP-1RA in the everyday clinical practice [PDF]

Gašper Tonin, Katja Goričar, Tanja Blagus, Andrej Janež, Vita Dolžan, Jasna Klen   +5 more
openalex   +1 more source

Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States

, 2022
Julie Z. Zhao, Eric D. Weinhandl, Angeline M. Carlson, Wendy L. St. Peter   +3 more
openalex   +1 more source

The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective

Obesity, EarlyView.
ABSTRACT The off‐label use of glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) among people without obesity and/or diabetes is rapidly expanding, despite a lack of clinical justification or safety data in this population. This Perspective explores the sociomedical dimensions of this trend, highlighting key research gaps and emerging hypotheses ...
Fernanda Baeza Scagliusi, Bruno Gualano, Pernille Andreassen, Cindi SturtzSreetharan, Sissel Due Jensen, Alexandra Brewis   +5 more
wiley   +1 more source

Contractile Effects of Glucagon in Mouse Cardiac Preparations. [PDF]

Int J Mol Sci
Neumann J, Schmidt F, Braekow P, Kirchhefer U, Klimas J, Hadova K, Gergs U.   +6 more
europepmc   +1 more source

Synergistic stimulation of Ca+ uptake by glucagon and Ca2+-mobilizing hormones in the perfused rat liver. A role for mitochondria in long-term Ca2+ homoeostasis [PDF]

, 1986
Joseph G. Altin, Fyfe L. Bygrave
openalex   +1 more source

Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials

Obesity, EarlyView.
ABSTRACT Objective This study compared the efficacy of metabolic/bariatric surgery (MBS) and GLP‐1 receptor agonists (GLP‐1 RAs), including dual GLP‐1/GIP analogues, for weight and metabolic outcomes in adults with obesity. Methods A network meta‐analysis of randomized controlled trials compared MBS or GLP‐1 RAs versus lifestyle intervention in adults ...
Lucas Sabatella, Patricia M. Ortega, Víctor Valentí Azcárate, Fernando Rotellar Sastre, Adriana Uriz Pagola, Ahmed Ahmed, Sanjay Purkayastha, Carlota Tuero Ojanguren, Nuria Blanco Asensio, Manuel F. Landecho   +9 more
wiley   +1 more source

Gut Peptide Alterations in Type 2 Diabetes and Obesity: A Narrative Review. [PDF]

Curr Obes Rep
Tzeravini E, Simati S, Anastasiou IA, Dalamaga M, Kokkinos A.   +4 more
europepmc   +1 more source

The Effect of Glucagon on the Serum Lipids in Rabbits with Experimental Diabetes

, 1958
Mitsuo Itô, Yukimasa Hirata
openalex   +2 more sources

Weekly Subcutaneous VK2735, a GIP/GLP‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study

Obesity, EarlyView.
Four doses of VK2735 and a placebo group were included in the VENTURE study. Adults who were overweight or had obesity had significant weight loss when taking any dose of VK2735 for 13 weeks. More people lost at least 10% of their body weight as the dose increased.
Harold E. Bays, Phillip Toth, Naim Alkhouri, John Pullman, Bradley Freilich, Joel Neutel, Summer Ji, Scott Stubbe, Parke Hedges, Brian Lian   +9 more
wiley   +1 more source